Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA announced the conversion of NOK 3,000,000 worth of convertible bonds into 4,975,399 new shares, increasing its share capital by NOK 2,985,239.40. This conversion, along with a previous one, will result in a total share capital of NOK 70,777,985.40, divided into 117,963,309 shares. This move reflects Circio’s strategic financial adjustments to support its ongoing biotechnology innovations and market positioning.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in the development of circular RNA vector expression technology for advanced gene and cell therapies. Their proprietary circVec platform enhances the biogenesis of multifunctional circRNA, offering significant improvements in RNA half-life and protein expression compared to traditional mRNA-based systems. The company also pursues immuno-oncology programs, notably the TG01 vaccine targeting RAS-mutated cancers.
Average Trading Volume: 2,145,568
Current Market Cap: NOK194.8M
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.